Yun Zhong
Stock Analyst at Wedbush
(3.65)
# 779
Out of 5,135 analysts
47
Total ratings
53.66%
Success rate
8.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $240 → $273 | $223.41 | +22.20% | 4 | Feb 12, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $17.88 | +90.16% | 13 | Jan 23, 2026 | |
| RZLT Rezolute | Maintains: Neutral | $1 → $2 | $3.63 | -44.90% | 2 | Jan 8, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $33 | $12.59 | +162.11% | 3 | Dec 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $16.52 | -3.15% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $3.89 | +105.66% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $82.46 | +4.29% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $17.52 | +2.74% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $8.82 | +353.77% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $5.15 | +443.69% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $3.41 | +134.60% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.06 | +97.04% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.31 | +866.77% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $4.04 | +593.07% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.58 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.30 | +11.89% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $21.75 | +111.49% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.42 | +2,305.58% | 1 | May 5, 2021 |
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $240 → $273
Current: $223.41
Upside: +22.20%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $17.88
Upside: +90.16%
Rezolute
Jan 8, 2026
Maintains: Neutral
Price Target: $1 → $2
Current: $3.63
Upside: -44.90%
Wave Life Sciences
Dec 12, 2025
Maintains: Outperform
Price Target: $20 → $33
Current: $12.59
Upside: +162.11%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $16.52
Upside: -3.15%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $3.89
Upside: +105.66%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $82.46
Upside: +4.29%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $17.52
Upside: +2.74%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $8.82
Upside: +353.77%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $5.15
Upside: +443.69%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $3.41
Upside: +134.60%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.06
Upside: +97.04%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.31
Upside: +866.77%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $4.04
Upside: +593.07%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.58
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.30
Upside: +11.89%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $21.75
Upside: +111.49%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.42
Upside: +2,305.58%